Swedish startup Ortivus, a small company that came onto the trial observation list at the Stockholm Exchange last year, has had the thumbs-up sign from the FDA to market their two main medical products, Mida and Mobimed, in the US Mida is a sophisticated heart monitoring device, Mobimed handles wireless two-way communication sending electro cardiogram and other medical data between an ambulance and the hospital. At present, already some 100 Swedish emergency units are equipped with Mobimed. Ortivus stock rocketed when introduced last year. First-year revenue was $8m with a net earning of some $800,000. Stock is expected to go still higher after this announcement.
